Pulmonary vascular disease research hub

Efficacy and safety of riociguat (MK-4836) in incipient pulmonary vascular disease as an indicator for early pulmonary arterial hypertension Double-blind, randomized, multicenter, multinational, placebo-controlled phase IIa study

This study is testing a new medicine called riociguat for a condition where blood vessels in the lungs become narrow. Researchers want to see if the medicine can help improve blood flow and if it's safe for people with early signs of this lung condition.